GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04 2022 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced
that it will present at the 40th Annual J.P. Morgan Healthcare
Conference on Tuesday, January 11, 2022, at 11:15 a.m. E.T.
The presentation and Q&A session will be webcast live from
GBT’s website at www.gbt.com in the Investors section. A replay of
the webcast will be archived and available for one month following
the event.
About Global Blood Therapeutics Global Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to
the discovery, development and delivery of life-changing treatments
that provide hope to underserved patient communities. Founded in
2011, GBT is delivering on its goal to transform the treatment and
care of sickle cell disease (SCD), a lifelong, devastating
inherited blood disorder. The company has introduced
Oxbryta® (voxelotor) tablets and tablets for oral suspension,
the first FDA-approved medicine that directly inhibits sickle
hemoglobin (HbS) polymerization, the root cause of red blood cell
sickling in SCD. GBT is also advancing its pipeline program in SCD
with inclacumab, a P-selectin inhibitor in Phase 3 development to
address pain crises associated with the disease, and GBT021601
(GBT601), the company’s next generation HbS polymerization
inhibitor. In addition, GBT’s drug discovery teams are working on
new targets to develop the next wave of potential treatments for
SCD. To learn more, please visit www.gbt.com and follow
the company on Twitter @GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney
Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024